AI Consensus Investment Thesis
Johnson & Johnson (JNJ) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Hold & Monitor
Model signals are balanced; wait for clearer evidence.
1-Year
NEUTRAL$267
+2.2%+4.3% incl. dividends5-Year
NEUTRAL$344
+32.0%+46.6% incl. dividendsLatest flagship insight
Why This Sovereign-Grade Healthcare Giant Faces a Silent Valuation Gravity Well
A sharp divergence exists between the market's safe-haven narrative and the mathematical reality of multiple contraction. While high consensus supports the asset's fortress balance sheet and robust free cash flow, the primary driver of predatory capital allocation is offset by regulatory pricing risks and patent cliff erosion.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset presents a classic dichotomy between operational excellence and valuation gravityvaluation gravityAn informal expression for the tendency of price to move toward levels supported by earnings, cash flow, or historical valuation norms.View full glossary entry. While the core business generates robust, inelastic free cash flowsfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry backed by a AAA-rated balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry, a starting valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry near thirty times trailing earnings creates a structural headwind. Over a five-year horizon, the base-case narrative projects steady fundamental compounding driven by MedTech integration, post-spinoff margin expansionmargin expansionAn increase in profit as a percentage of revenue.View full glossary entry, and predatory capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry targeting distressed biotech assets. However, this intrinsic compounding will likely be offset by multiple contraction as the market adjusts to a higher-for-longer interest rate regimeinterest rate regimeA persistent pattern in policy rates and market yields that shapes borrowing costs, discount rates, and asset values.View full glossary entry and regulatory pricing constraints.
Key insights
- Pristine AAA-rated balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry provides a permanent cost-of-capital advantage and unconstrained optionality for counter-cyclical M&A.
- Post-spinoff operational purity drives gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry to seventy-three percent, insulating earnings from inflationary shocks.
- The impending Stelara patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry acts as a telegraphed headwind, requiring flawless pipeline execution to offset revenue decay.
- Restrictive monetary policy and elevated risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry exert persistent downward pressure on premium valuation multiples.
- Bipartisan drug pricing initiatives and international reference pricing frameworks place a structural ceiling on domestic net realized prices.
- Shareholder returns will be heavily supported by a reliable dividend yielddividend yieldA financial ratio showing how much a company pays out in dividends each year relative to stock price.View full glossary entry and disciplined, opportunistic share repurchases.
- Disagreements persist regarding the speed of pipeline replacement and the ultimate financial impact of legacy mass-tort litigation.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The general market consensus views the asset as the ultimate macroeconomic safe haven and a bulletproof, AAA-rated dividend aristocrat. Investors treat the stock as a reliable bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry, anchoring heavily on its sixty-year history of dividend increases and robust healthcare demand to weather global conflicts, energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry, and market volatility. The prevailing narrative assumes that safety at any price is a virtue, largely ignoring the valuation risks of paying a premium multiple for mid-single-digit growth. Additionally, the media remains highly distracted by the sensationalism of legacy talc litigation and patent cliffs, treating these as existential threats while overlooking the operational leverage gained from recent corporate spin-offs.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the decoupling of business quality from investment quality. While the crowd correctly identifies the asset as an impenetrable commercial fortress, it misprices the security by conflating business safety with investment safety. Paying a premium multiple for a mature enterprise facing patent cliffs in a high-rate environment leaves zero margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry, transforming a phenomenal business into a mediocre entry point. Furthermore, the market overlooks the predatory advantage of holding a AAA-equivalent balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry in a capital-scarce regime. While high rates suffocate subscale biotech funding, the asset can acquire distressed innovation at generational lows. The variant perceptionvariant perceptionAn investment view that differs from market consensus and assumes future outcomes will be better or worse than widely expected.View full glossary entry is that the asset is not a passive bond proxybond proxyAn equity or other asset valued partly for stable income and therefore often sensitive to changes in bond yields.View full glossary entry, but a highly concentrated, pure-play biopharma and advanced medical technology apex predator capable of offensive capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? The valuation gapvaluation gapThe difference between a market price and an analyst's estimate of intrinsic value.View full glossary entry is expected to close within the next twelve to eighteen months, triggered by a combination of operational and corporate events. The primary catalyst will be the announcement of a highly accretive, cash-funded acquisition of a distressed biotech asset, proving the power of the company's capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry machinery. Additionally, the formal filing and execution of the planned orthopaedics division spin-off will force analysts to strip out low-margin drags from their models. These events, paired with earnings reports demonstrating successful pipeline backfill execution, will force the market to re-rate the remaining high-margin biopharma and advanced medical technology segments.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Low Steady
- Cycle position
- Growing Awareness
While there is strong consensus that expected volatility will remain low and steady, there is material disagreement regarding the market's current position in the convergence cycle. Some perspectives suggest the asset is in an overshoot phase driven by defensive panic, while others argue it is in the early discovery or growing awareness stage of its structural margin transformation.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry presents a bifurcated setup for the asset. Restrictive monetary policy, characterized by higher-for-longer interest rates and sticky inflation, acts as a valuation headwind. Because the stock is often treated as a bond equivalent, high risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry directly compete with its dividend, exerting downward pressure on its premium multiple. Conversely, this stagflationary environmentstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry provides a powerful operational tailwind. Inelastic healthcare demand shields the core business from economic downturns, while capital scarcity crushes cash-burning competitors. This allows the company to leverage its pristine balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry to acquire distressed innovation, converting macro headwindsmacro headwindsBroad economic conditions that can slow growth, weaken demand, or pressure asset valuations.View full glossary entry into a long-term competitive advantage.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the starting valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry and the timing of multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. Some perspectives argue that the current premium multiple is a temporary safe-haven anomaly that will contract rapidly as risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry remain elevated. Others contend that the premium is justified by the company's structural margin expansionstructural margin expansionA durable increase in profit margins driven by lasting changes in mix, pricing, scale, technology, or cost structure.View full glossary entry post-spinoff and its predatory capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry advantages. Additionally, there is divergence regarding the speed at which the new immunology and oncology pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry can offset the Stelara patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry, with estimates of revenue stabilization ranging from twelve months to three years.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Predatory Capital Allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry | Capital Allocation | +18% | +15% | The asset's pristine AAA-rated balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry and massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry function as powerful offensive weapons in a high-rate environment. While early-stage biotechnology firms face severe funding constraints and compressed valuations, this enterprise can execute highly accretive, counter-cyclical acquisitions of de-risked pipelines at distressed multiples. This structural capital advantage allows the company to replenish its patent portfolio and expand its market share without relying on expensive external debt markets, driving long-term intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry compounding. |
| Post-Spinoff Margin Accretion | Operational Efficiency | +14% | +11% | Following the strategic divestiture of its lower-margin consumer health division, the enterprise has structurally elevated its gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry to approximately seventy-three percent. This operational purity concentrates management focus and capital exclusively on high-barrier, high-margin biopharma and advanced medical technology segments. The planned separation of the capital-intensive orthopaedics unit will further streamline operations, driving return on equityreturn on equityReturn on equity (ROE) measures net income generated relative to shareholders' equity over a given period.View full glossary entry higher and insulating consolidated earnings from stagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry input cost pressures. |
| Inelastic Biological Demand | Sector And Industry | +12% | +14% | The fundamental demographic reality of a rapidly aging global population ensures a non-discretionary, compounding demand for oncology, immunology, and advanced MedTech interventions. Because these medical treatments are essential for life preservation, demand remains highly inelastic during macroeconomic downturns. This biological anchoring provides a highly predictable, recession-resistant revenue floor, allowing the company to maintain pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and stable cash flows despite broader geopolitical and economic volatility. |
| BIOSECURE Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry Moat | Competitive Positioning | +8.0% | +6.0% | As legislative mandates force life-science supply chains to decouple from Chinese biomanufacturing providers, smaller competitors face severe transition costs and operational bottlenecks. In contrast, this enterprise's massive, globally diversified internal manufacturing footprint and proactive domestic onshoring strategy act as a major competitive advantage. By seamlessly navigating these regulatory shifts, the company is positioned to capture market share abandoned by exposed rivals. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Valuation Multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry Gravity | Macroeconomic And Macrofinancial | -20% | -0.0% | Trading at a premium multiple of approximately thirty times trailing earnings, the stock leaves zero margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry for a mature enterprise growing revenues at a mid-single-digit pace. In a macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry where risk-free Treasury yields remain elevated above four percent, paying such a premium is mathematically unsustainable. This valuation friction guarantees persistent multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry over the forecast horizon, dragging on price appreciation even if operational targets are met. |
| Stelara Patent Cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry Erosion | Competitive Positioning | -12% | -14% | The loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry for the blockbuster immunology drug Stelara exposes a multi-billion dollar, high-margin revenue stream to intense biosimilar competitionbiosimilar competitionCompetition from highly similar versions of an approved biologic medicine after exclusivity or market protections weaken.View full glossary entry. This telegraphed erosion is accelerated by major pharmacy benefit managers removing the drug from key formularies. While the company's pipeline is designed to backfill this revenue crater, the sheer scale of the legacy franchise ensures a persistent near-term drag on consolidated earnings growth. |
| Sovereign Drug Pricing Constraints | Regulatory | -10% | -11% | Bipartisan political pressure, including the implementation of price-capping frameworks and Medicare drug price negotiations, places a hard ceiling on net realized prices for blockbuster therapies. This regulatory intervention directly targets the traditional mechanism of utilizing routine price hikes to offset R&D inflation. The resulting margin squeezemargin squeezePressure on profits when costs rise faster than selling prices.View full glossary entry limits the terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry of the pharmaceutical pipeline, forcing reliance on volume expansion. |
| Persistent Litigation Liabilities | Management And Governance | -6.0% | -5.0% | The ongoing mass-tort litigation regarding legacy talcum powder products remains a persistent financial and narrative drag. Despite extensive corporate restructuring and bankruptcy maneuvers designed to ring-fence these liabilities, the legal architecture remains fragile. The continuous need to fund legal defense costs and maintain massive cash reserves for potential settlements siphons billions away from productive R&D and shareholder buybacks. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Mass Tort Ring-Fence Failure | 22% | -20% | Regulatory | A definitive judicial rejection of the corporate restructuring bankruptcy strategy, exposing the parent company's balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry to uncapped state-level mass tort claims. This would trigger cascading, multi-billion-dollar punitive verdicts, forcing massive reserve charges, threatening the dividend growth trajectory, and causing a severe institutional sell-off. |
| Critical Pipeline Attrition | 20% | -18% | Innovation And Product | A catastrophic late-stage clinical failure or severe FDA safety warning for a key replacement growth driver. This would expose a massive revenue hole precisely as legacy blockbusters face biosimilar erosion, shifting the market narrative from a growth transition to structural declinestructural declineA long-term weakening trend caused by persistent business or industry headwinds.View full glossary entry and triggering severe multiple contraction. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Global Talc Litigation Settlement | 38% | +14% | Regulatory | A definitive, plaintiff-approved global settlement or federal legislative shield that permanently ring-fences and caps legacy talc liabilities. This would instantly remove the largest unquantifiable legal tail risk depressing the stock's valuation, lowering the equity risk premium and allowing the market to re-rate the stock based on its fundamental cash flows. |
| Transformational Oncology Breakthrough | 32% | +15% | Innovation And Product | An unexpected late-stage clinical breakthrough or accelerated FDA approval for a novel, high-TAMtotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry targeted oncology or immunology asset. This would establish a highly profitable, patent-protected monopoly that outpaces the Stelara patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry, forcing a rapid upward revision of the pipeline's terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry. |
Company Financial Analysis
Johnson & Johnson Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's financial engine remains incredibly strong, but it is currently facing a period of transition. On the positive side, the business generates a massive and stable flow of cash, bringing in nearly twenty billion dollars in free cash flow annually, with overall revenues growing at a healthy six percent. However, the company's net income has shown some short-term volatility due to one-time legal settlements and the loss of patent protection on its major drug, Stelara. Most assessments agree that the underlying cash generation is bulletproof and highly valuable in today's uncertain economy. The main area of disagreement is whether the company's slow-and-steady growth can justify its currently high stock price. While some believe the steady cash flow makes it a safe bet, others warn that investors are paying too much of a premium, which could limit future stock gains.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 94.2B | USD 26.8B | USD 19.7B |
| 2024 | USD 88.8B | USD 14.1B | USD 19.8B |
| 2023 | USD 85.2B | USD 35.2B | USD 18.2B |
| 2022 | USD 80B | USD 17.9B | USD 17.2B |
| 2021 | USD 78.7B | USD 20.9B | USD 19.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.8x | TTM | Native | USD / USD |
| 2024 | 25.0x | TTM | Native | USD / USD |
| 2023 | 10.8x | TTM | Native | USD / USD |
| 2022 | 26.2x | Annual | Native | USD / USD |
| 2021 | 21.9x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company boasts elite profitability, with gross margins stabilizing at an impressive seventy-three percent and operating margins hovering around twenty-seven percent. This incredible profitability is a direct result of selling off its lower-margin consumer health division, leaving a highly focused and efficient business. There is strong consensus that these high margins provide an excellent buffer against inflation and rising supply chain costs. However, there is a clear clash of opinions regarding the future path of these margins. Some analysts believe that upcoming government rules to cap drug prices and the rising costs of manufacturing products domestically will put a ceiling on profits, causing margins to shrink slightly. Others argue that the company's transition into high-margin robotic medical devices and advanced cancer therapies will offset these pressures, allowing profitability to remain at historic highs.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 25.6B | 27.2% | 28.5% |
| 2024 | USD 22.1B | 24.9% | 15.8% |
| 2023 | USD 21.9B | 25.7% | 41.3% |
| 2022 | USD 21B | 26.3% | 22.4% |
| 2021 | USD 20.9B | 26.6% | 26.5% |
Balance sheet and leverage
The company's balance sheet is widely recognized as an absolute financial fortress, boasting one of the very few remaining AAA credit ratings in the corporate world. With a very conservative debt level and massive interest coverage, the company is completely insulated from the pressure of high interest rates. There is high consensus that this financial strength provides incredible safety during economic downturns. Furthermore, it gives the company a unique offensive advantage: while smaller, cash-strapped competitors struggle to survive, this giant can use its massive cash reserves to buy up promising new drug technologies at bargain prices. The only notable concern or point of caution is the massive, off-balance-sheet risk of tens of thousands of ongoing lawsuits. While the company's financial safety net is strong enough to absorb these legal costs, a failure to settle these cases could eventually drain cash that would otherwise go to stock buybacks.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 47.9B | USD 20.1B | USD 28.2B net debt | 1.03x |
| 2024 | USD 36.6B | USD 24.5B | USD 12.5B net debt | 1.11x |
| 2023 | USD 29.3B | USD 22.9B | USD 7.5B net debt | 1.16x |
| 2022 | USD 39.6B | USD 22.3B | USD 26.8B net debt | 0.99x |
| 2021 | USD 33.8B | USD 31.6B | USD 19.3B net debt | 1.35x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company operates a highly efficient business model that does not require heavy spending on physical factories or equipment, which typically consumes only about five percent of its revenue. Instead, the real heavy lifting is done through its massive research and development budget, which stands at nearly fifteen billion dollars annually. This heavy spending is absolutely necessary to discover new treatments and protect the company's business from losing patents on older drugs. There is strong consensus that this self-funded investment strategy is a major advantage because the company does not need to borrow expensive money to grow. However, opinions differ on the efficiency of this spending. Some believe the company's shift toward advanced digital and artificial intelligence tools will make drug discovery faster and cheaper, while others worry the company is overpaying for outside acquisitions to plug its revenue holes.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 4.8B | USD 14.7B |
| 2024 | USD 4.4B | USD 17.2B |
| 2023 | USD 4.5B | USD 15B |
| 2022 | USD 4B | USD 14.1B |
| 2021 | USD 3.7B | USD 14.3B |
Quarterly Forecast Scenarios
Johnson & Johnson Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $252.52 | $263.48 | $273.56 | $736.09 | |
| $244.94 | $264.30 | $281.77 | $724.14 | |
| $240.04 | $264.38 | $287.40 | $713.57 | |
| $235.24 | $266.52 | $298.90 | $723.38 | |
| $237.50 | $271.58 | $304.88 | $716.61 | |
| $232.84 | $275.06 | $314.02 | $738.34 | |
| $230.52 | $277.69 | $320.27 | $746.91 | |
| $230.52 | $282.06 | $336.29 | $771.93 | |
| $235.13 | $288.86 | $343.01 | $782.73 | |
| $227.89 | $294.68 | $349.87 | $807.31 | |
| $225.61 | $298.37 | $360.37 | $822.72 | |
| $230.12 | $303.04 | $367.58 | $846.10 | |
| $230.12 | $305.70 | $374.93 | $852.53 | |
| $232.42 | $313.29 | $382.43 | $882.91 | |
| $227.77 | $317.84 | $382.43 | $900.46 | |
| $230.05 | $321.56 | $386.25 | $922.67 | |
| $227.75 | $324.01 | $393.98 | $935.91 | |
| $223.19 | $330.74 | $401.86 | $952.30 | |
| $225.43 | $337.51 | $409.89 | $976.28 | |
| $225.43 | $344.32 | $418.09 | $1,002 |
Research Provenance
References & Context
This Johnson & Johnson consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2007-01-01–2026-01-01, 20 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).